China's NCI Approval Updates: Evonik and L'Oréal Join Forces on a New NCI in China
From January 16 to 23, 2026, 3 new cosmetic ingredients (NCIs) have completed notifications with China's National Medical Products Administration (NMPA). The technical requirements for the 3 NCIs mentioned above have not been disclosed, and they have not yet entered the safety monitoring period. Marubi's Fifth NCI Notification Gynura divaricata (L.) DC., a member of the Gynura genus in the Asteraceae family, is recognized in China as a medicinal and edible plant. It contains a range of bioactive constituents, including polysaccharides, flavonoids, alkaloids, and anthraquinones, and is associated with anti-inflammatory, hepatoprotective, and lipid-lowering activities. In 2010, China's former Ministry of Health (now the National Health